WEKO3
アイテム
{"_buckets": {"deposit": "76ee4873-51e2-432e-9103-f96ce1bda919"}, "_deposit": {"created_by": 1, "id": "44880", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "44880"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00044880", "sets": ["1"]}, "author_link": ["445755", "445745", "445747", "445751", "445750", "445752", "445754", "445746", "445753", "445748", "445749"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2006-06", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "11", "bibliographicPageEnd": "1579", "bibliographicPageStart": "1575", "bibliographicVolumeNumber": "94", "bibliographic_titles": [{"bibliographic_title": "British Journal of Cancer"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients. Patients who had pathologically proven pancreatic cancer with metastatic lesions were eligible candidates for entry into the study. S-1 was given orally (30 mg m(-2)) b.i.d. for 14 consecutive days and gemcitabine (1000 mg m(-2)) was given on days 8 and 15. The cycle was repeated every 21 days. We enrolled 33 MPC patients. The median number of cycles was eight (range 1-20). Grade 3-4 toxicities were leucopenia (33%), neutropenia (55%), anaemia (9%), thrombocytopenia (15%), anorexia (6%), fever (9%), and interstitial pneumonia (6%). Objective responses were obtained in 16 patients (one complete response and 15 partial responses; response rate, 48%; 95% confidence interval (CI), 33-65). Median survival and 1-year survival rate were 12.5 months (95% CI, 5.9-19.1) and 54% (95% CI, 36-72), respectively. Combination chemotherapy with GEM and S-1 was well tolerated and yielded a significantly high response rate.", "subitem_description_type": "Abstract"}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0007-0920", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nakamura, Kazutaka"}], "nameIdentifiers": [{"nameIdentifier": "445745", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamaguti, Taketo"}], "nameIdentifiers": [{"nameIdentifier": "445746", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishihara, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "445747", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kobayashi, Akitoshi"}], "nameIdentifiers": [{"nameIdentifier": "445748", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tadenuma, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "445749", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sudo, Kentaro"}], "nameIdentifiers": [{"nameIdentifier": "445750", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katou, Hirotoshi"}], "nameIdentifiers": [{"nameIdentifier": "445751", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saisho, Hiromitsu"}], "nameIdentifiers": [{"nameIdentifier": "445752", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "山口 武人", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "445753", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "加藤 博敏", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "445754", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "税所 宏光", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "445755", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/44880", "pubdate": {"attribute_name": "公開日", "attribute_value": "2007-06-15"}, "publish_date": "2007-06-15", "publish_status": "0", "recid": "44880", "relation": {}, "relation_version_is_last": true, "title": ["Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer"], "weko_shared_id": -1}
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
https://repo.qst.go.jp/records/44880
https://repo.qst.go.jp/records/44880f612b552-35e4-4d46-85ee-83d1d236c0e3
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2007-06-15 | |||||
タイトル | ||||||
タイトル | Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Nakamura, Kazutaka
× Nakamura, Kazutaka× Yamaguti, Taketo× Ishihara, Takeshi× Kobayashi, Akitoshi× Tadenuma, Hiroshi× Sudo, Kentaro× Katou, Hirotoshi× Saisho, Hiromitsu× 山口 武人× 加藤 博敏× 税所 宏光 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients. Patients who had pathologically proven pancreatic cancer with metastatic lesions were eligible candidates for entry into the study. S-1 was given orally (30 mg m(-2)) b.i.d. for 14 consecutive days and gemcitabine (1000 mg m(-2)) was given on days 8 and 15. The cycle was repeated every 21 days. We enrolled 33 MPC patients. The median number of cycles was eight (range 1-20). Grade 3-4 toxicities were leucopenia (33%), neutropenia (55%), anaemia (9%), thrombocytopenia (15%), anorexia (6%), fever (9%), and interstitial pneumonia (6%). Objective responses were obtained in 16 patients (one complete response and 15 partial responses; response rate, 48%; 95% confidence interval (CI), 33-65). Median survival and 1-year survival rate were 12.5 months (95% CI, 5.9-19.1) and 54% (95% CI, 36-72), respectively. Combination chemotherapy with GEM and S-1 was well tolerated and yielded a significantly high response rate. | |||||
書誌情報 |
British Journal of Cancer 巻 94, 号 11, p. 1575-1579, 発行日 2006-06 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0007-0920 |